甲磺酸阿帕替尼三线治疗晚期非小细胞肺癌患者的疗效及安全性分析

doi:10.12092/j.issn.1009-2501.2019.05.014

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (5): 567-572.doi: 10.12092/j.issn.1009-2501.2019.05.014

甲磺酸阿帕替尼三线治疗晚期非小细胞肺癌患者的疗效及安全性分析

王海莉¹，巩天晓¹，周士霞¹，梅家转²，张中冕¹

¹郑州大学第二附属医院肿瘤科，郑州 450014，河南；²郑州人民医院肿瘤科，郑州 450000，河南

收稿日期:2019-02-13 修回日期:2019-03-19 出版日期:2019-05-26 发布日期:2019-05-28
通讯作者: 张中冕，男，硕士，主任医师，研究方向：肿瘤的基础与临床研究。 Tel: 13613835778 E-mail: 13613835778@163.com
作者简介:王海莉，女，硕士，主治医师，研究方向：肿瘤的基础与临床研究。 Tel: 13633826926 E-mail: hnwanghaili@163.com
基金资助:
河南省郑州市科技计划项目（141PPTGG315）

Efficacy and safety of third-line treatment with mesylate apatinib in patients with advanced non-small cell lung cancer

WANG Haili¹, GONG Tianxiao¹, ZHOU Shixia¹, MEI Jiazhuan², ZHANG Zhongmian ¹

¹Department of Oncology, the Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, Henan, China; ²Department of Oncology, People's Hospital of Zhengzhou, Zhengzhou 450000, Henan, China

Received:2019-02-13 Revised:2019-03-19 Online:2019-05-26 Published:2019-05-28

摘要/Abstract

摘要：

目的:本研究旨在观察并探讨甲磺酸阿帕替尼三线治疗晚期非小细胞肺癌患者的疗效及安全性。方法: 本研究为回顾性分析，从2015年3月到2018年6月纳入接受甲磺酸阿帕替尼治疗的96例晚期非小细胞肺癌患者作为研究对象，对疗效及安全性进行回顾性分析。96例晚期非小细胞肺癌患者接受甲磺酸阿帕替尼进行治疗2个周期后观察并分析临床疗效及基质金属蛋白酶（MMP-9）、血管内皮生长因子（VEGF）和癌胚抗原（CEA）等指标的变化情况，评价客观缓解率（ORR），疾病控制率（DCR），随后评价无进展生存期（PFS）和总生存期（OS），并记录安全性数据。结果:96例患者均可评价疗效，其中完全缓解（CR）0例，部分缓解（PR）16例，疾病稳定（SD）54例，疾病进展26例。ORR为16.67%，DCR为72.92%。MMP-9、VEGF和CEA指标与治疗后相比，差异存在统计学意义（P<0.05）。中位无进展生存期（mPFS）为4.65个月。中位总生存期（mOS）为8.90个月。安全性方面，发生率较高的3级以上不良反应为高血压13例（13.54%），手足综合征9例（9.75%），蛋白尿7例（7.29%），咯血7例（7.29%），疲劳6例（6.25%），高甘油三酯血症4例（4.17%）。结论:甲磺酸阿帕替尼治疗晚期非小细胞肺癌具有一定的临床疗效，安全性事件总体可控。

关键词: 非小细胞肺癌, 甲磺酸阿帕替尼, 疗效, 安全性

Abstract:

AIM: To investigate and explore the efficacy and safety of third line treatment of mesylate apatinib in patients with advanced non-small cell lung cancer. METHODS: Designed as a retrospective study, a total of 96 patients with advanced non-small cell lung cancer from March 2015 to June 2018 were included in this study, and the clinical data and clinical outcomes were retrospectively analyzed. The 96 patients with advanced non-small cell lung cancer were treated with mesylate apatinib until the disease progress. The clinical efficacy and changes of MMP-9, VEGF and CEA were observed after two cycles treatment. The objective remission rates (ORR), disease control rates (DCR), progression-free survival (PFS) and overall survival (OS) were evaluated and safety data were recorded. RESULTS:All of the 96 patients were available for efficacy evaluation, among them, complete remission (CR) 0 cases, partial remission (PR) 16 cases, stable disease (SD) 54 cases and progression disease (PD) 26 cases. The objective remission rate (ORR) was 16.67%, and the disease control rate (DCR) was 72.92%. There were significant differences in MMP-9, VEGF and CEA between before treatment group and after treatment group (P<0.05). The median progression-free survival (mPFS) was 4.65 months. The median overall survival (mOS) was 8.90 months. In terms of safety analysis, grade 3 and above adverse reactions with high incidence were hypertension (13.54%), hand-foot syndrome (9.75%), proteinuria (7.29%), hemoptysis (7.29%), fatigue (6.25%) and hypertriglyceridemia (4.17%). CONCLUSION:Mesylate apatinib is effective and safe in the treatment of advanced non-small cell lung cancer.

Key words: non-small cell lung cancer, mesylate apatinib, efficacy, safety

中图分类号:

R734.2

王海莉，巩天晓，周士霞，梅家转，张中冕. 甲磺酸阿帕替尼三线治疗晚期非小细胞肺癌患者的疗效及安全性分析[J]. 中国临床药理学与治疗学, 2019, 24(5): 567-572.

WANG Haili, GONG Tianxiao, ZHOU Shixia, MEI Jiazhuan, ZHANG Zhongmian. Efficacy and safety of third-line treatment with mesylate apatinib in patients with advanced non-small cell lung cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 567-572.

参考文献

［1］Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015［J］. CA Cancer J Clin, 2016, 66(2):115-132.
［2］王海霞, 刘兴安, 侯继院, 等. KDR基因遗传变异对贝伐珠单抗一线治疗晚期非小细胞肺癌患者临床疗效的影响［J］. 中国临床药理学与治疗学, 2018, 23(7): 802-808.
［3］宋勇, 高健伟. 精准医学时代的晚期非小细胞肺癌内科治疗进展［J］. 医学研究生学报, 2017, 30(11): 1121-1127.
［4］Yang Z, Tam KY. Combination strategies using EGFR-TKI in NSCLC therapy: learning from the gap between pre-clinical results and clinical outcomes［J］. Int J Biol Sci, 2018, 14(2): 204-216.
［5］贺利平, 陈毅斐, 杨炯. 前列腺素合成酶D2对非小细胞肺癌的作用及机制探讨［J］. 中华医学杂志, 2017, 97(38): 3022-3027.
［6］Toffalorio F, Santarpia M, Radice D, et al. 5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer［J］. Oncotarget, 2018, 9(23): 16437-16450.
［7］Zhou C, Wu YL, Chen G, et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer［J］. J Clin Oncol, 2015, 33(19): 2197-2204.
［8］Gridelli C, Baas P, Barlesi F, et al. Second-line treatment options in non-small-cell lung cancer: report from an international experts panel meeting of the italian association of thoracic oncology［J］. Clin Lung Cancer, 2018, 19(4): 301-314.
［9］Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial［J］. JAMA Oncol, 2018, 4(11): 1569-1575.
［10］Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction［J］. J Clin Oncol, 2016, 34(13): 1448-1454.
［11］李萍, 马薇, 周荣. 非小细胞肺癌靶向治疗药物的研究进展［J］. 药学与临床研究, 2017, 25(4): 130-136.
［12］陈玲娟, 伍钢, 董晓荣. 阿帕替尼二线及二线以上治疗晚期肺癌26例［J］. 医药导报, 2018, 37(5): 551-554.
［13］Shu T, Haitian Q, Chengying X, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo［J］. Cancer Sci, 2011, 102(7): 1374-1380.
［14］Aguiar-Bujanda D, Duenas-Comino A, Saura-Grau S, et al. Neutrophil to lymphocyte ratio as a prognostic factor in european patients with epidermal growth factor receptor-mutant non-small cell lung cancer treated with tyrosine kinase inhibitors［J］. Oncol Res Treat, 2018, 41(12): 755-761.
［15］Fang S, Zhang M, Wei G, et al. Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR［J］. Oncotarget, 2018, 9(6): 7175-7181.
［16］Zhang D, Zhang C, Huang J, et al. Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study［J］. Thorac Cancer, 2018, 9(12): 1754-1762.
［17］Wu D, Liang L, Nie L, et al. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC［J］. Asia Pac J Clin Oncol, 2018, 14(6): 446-452.
［18］Li T, Wang SB, Lei KJ, et al. Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer: A case report［J］. Medicine (Baltimore), 2019, 98(4): e14182.

[1]	许宜琪, 吴茜, 刘书, 刘帆, 邢春燕, 李勤, 何俊俊, 何春玲, 赵咏莉, 高家林. 雷公藤多苷治疗糖尿病肾脏病的临床疗效及抗炎抗纤维化分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1034-1042.
[2]	肖悦, 李唐菲, 薛乾富. 聚乙二醇干扰素-α治疗原发性血小板增多症的疗效和安全性分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1049-1055.
[3]	刘敏, 孔祥, 章叶, 顾逸飞, 项雪梅, 黄凯. 经口吸入制剂在中国健康受试者生物等效性试验中的安全性分析[J]. 中国临床药理学与治疗学, 2023, 28(10): 1131-1138.
[4]	黄小明, 杜野, 林少明, 沈观乐. 呼吸道微生态对晚期非小细胞肺癌患者接受PD-1抑制剂单药治疗疗效影响的探索性研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 66-74.
[5]	张可心, 贾文静, 崔佳文, 敖路遥, 周芳, 王广基, 刘嘉莉. 第三代EGFR酪氨酸激酶抑制剂在非小细胞肺癌临床治疗中的应用及研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1016-1030.
[6]	梁美芳, 陈庆状, 杨沛群, 王勇. 基于真实世界的阿托伐他汀仿制药和原研药防治缺血性脑卒中/短暂性脑缺血发作的有效性和安全性比较[J]. 中国临床药理学与治疗学, 2022, 27(7): 785-792.
[7]	晏玉奎, 胡建琴, 张冰. 新型和传统抗癫痫药物治疗新诊断部分性癫痫的临床研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 793-799.
[8]	鲍静, 陈晓文, 夏亮, 赵雨辰, 夏瑞祥, 夏海龙. 伊沙佐米治疗多发性骨髓瘤的临床疗效和安全性分析[J]. 中国临床药理学与治疗学, 2021, 26(7): 782-786.
[9]	黄伊婷, 沈爱宗. 阿法替尼治疗肺癌的临床疗效与安全性[J]. 中国临床药理学与治疗学, 2021, 26(4): 474-480.
[10]	李静, 马丽娟, 袁圆, 王捷, 郁长治, 赵军. 吸入性糖皮质激素布地奈德相关基因多态性与哮喘疗效的关系[J]. 中国临床药理学与治疗学, 2021, 26(11): 1250-1258.
[11]	裴清华, 孙建立. 奥希替尼获得性耐药的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(1): 105-112.
[12]	林荣芳, 郑玮玮, 刘亦伟, 林翠鸿, 王长连, 黄品芳. 克罗恩病患者英夫利西单抗相关基因多态性与血药浓度及疗效关联性研究[J]. 中国临床药理学与治疗学, 2020, 25(9): 1000-1006.
[13]	魏为添, 陈晟, 汪亮, 曾剑. 灯盏花素对非小细胞肺癌A549细胞的促凋亡作用[J]. 中国临床药理学与治疗学, 2020, 25(6): 618-624.
[14]	赵倩，杨广，曹莉华，于陈宝. CNR1基因遗传变异对利拉鲁肽治疗早期2型糖尿病患者临床疗效的影响[J]. 中国临床药理学与治疗学, 2020, 25(2): 182-188.
[15]	潘露萍，石武杰，沈志鹏. 依托泊苷联合卡铂用于复发性髓母细胞瘤患儿的疗效与安全性[J]. 中国临床药理学与治疗学, 2020, 25(2): 189-195.

甲磺酸阿帕替尼三线治疗晚期非小细胞肺癌患者的疗效及安全性分析

Efficacy and safety of third-line treatment with mesylate apatinib in patients with advanced non-small cell lung cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价